BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...
SAN DIEGO and CHICAGO, June 30, 2025 /PRNewswire/ -- HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition...
En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, offrant le potentiel de blocage de la progression de la maladie1
Sinu-9 currently producing over 12 MMcf/d, expected to increase to a minimum of 15 MMcf/d in early July 2025 Expansion of processing and compression...
ST. PAUL, Minn., June 19, 2025 /PRNewswire/ -- Johnson//Becker, PLLC, is a national product liability law firm with a strong track record of representing...